Literature DB >> 2039842

An efficient method for culturing human breast carcinoma to evaluate antiblastic drug activity in vitro: experience on 136 primary cancers and on 116 recurrences.

W Zoli1, A Volpi, C Bonaguri, A Riccobon, S Savini, R Brizio, A Saragoni, L Medri, G A Marra, D Amadori.   

Abstract

The feasibility of techniques developed for isolating and culturing human mammary epithelial cells of malignant origin was confirmed in 136 primary breast cancers, 116 hypodermal metastases, and 8 metastatic lymph nodes. In 115 (84%) primary breast cancers and in 81 (70%) hypodermal recurrences we observed a good in vitro cellular proliferation. These proliferating cells, at the second passage, were used for a clonal assay suitable for quantitating drug sensitivity. With this clonal assay median cloning efficiencies of 14% and 6% were obtained respectively in primaries and in skin recurrences. We examined the in vitro response to different drugs and confirmed the test's ability to detect heterogeneity in response to same drugs (doxorubicin, 4'-epidoxorubicin, vinblastine, cis platinum, and idarubicinol) among the different breast carcinoma cultures as well as heterogeneity among subpopulations within a single carcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039842     DOI: 10.1007/bf01806372

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

1.  Predictive relevance for clinical outcome of in vitro sensitivity evaluated through antimetabolic assay.

Authors:  R Silvestrini; O Sanfilippo; M G Daidone; N Zaffaroni
Journal:  Recent Results Cancer Res       Date:  1984

2.  Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma.

Authors:  S K Moot; G N Peters; J H Cheek
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

3.  Cell proliferation and its relationship to clinical features and relapse in breast cancers.

Authors:  C Gentili; O Sanfilippo; R Silvestrini
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

4.  Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations.

Authors:  C A Bertelsen; V K Sondak; B D Mann; E L Korn; D H Kern
Journal:  Cancer       Date:  1984-03-15       Impact factor: 6.860

5.  Human tumor colony assay and chemosensitivity testing.

Authors:  S E Salmon
Journal:  Cancer Treat Rep       Date:  1984-01

6.  Prediction of early course of breast carcinoma by thymidine labeling.

Authors:  J S Meyer; E Friedman; M M McCrate; W C Bauer
Journal:  Cancer       Date:  1983-05-15       Impact factor: 6.860

7.  Cell kinetics as a prognostic marker in node-negative breast cancer.

Authors:  R Silvestrini; M G Daidone; G Gasparini
Journal:  Cancer       Date:  1985-10-15       Impact factor: 6.860

8.  Fibronectin production by human mammary cells.

Authors:  M R Stampfer; I Vlodavsky; H S Smith; R Ford; F F Becker; J Riggs
Journal:  J Natl Cancer Inst       Date:  1981-08       Impact factor: 13.506

9.  Histopathological characterization of a novel monoclonal antibody, MLuC1, reacting with lung carcinomas.

Authors:  R Agresti; R Alzani; S Andreola; V Bedini; S Gianì; S Ménard; F Rilke; M I Colnaghi
Journal:  Tumori       Date:  1988-08-31

10.  The human tumour cloning assay in the management of breast cancer patients.

Authors:  C Dittrich; R Jakesz; F Wrba; L Havelec; O Haas; J Spona; H Holzner; R Kolb; K Moser
Journal:  Br J Cancer       Date:  1985-08       Impact factor: 7.640

View more
  5 in total

1.  Selective growth of freshly isolated human breast epithelial cells cultured at low concentrations in the presence or absence of bone marrow cells.

Authors:  J T Emerman; J Stingl; A Petersen; E J Shpall; C J Eaves
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 2.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.

Authors:  S Savini; W Zoli; O Nanni; A Volpi; G L Frassineti; E Magni; A Flamigni; A Amadori; D Amadori
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Establishment and characterization of a new cell line from primary human breast carcinoma.

Authors:  D Amadori; L Bertoni; A Flamigni; S Savini; C De Giovanni; S Casanova; F De Paola; A Amadori; E Giulotto; W Zoli
Journal:  Breast Cancer Res Treat       Date:  1993-12       Impact factor: 4.872

5.  In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.

Authors:  W Zoli; A Flamigni; G L Frassineti; P Bajorko; F De Paola; C Milandri; D Amadori; A Gasperi-Campani
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.